Chemosensitivity of miRNA-17-92 high expression in leukemia animal models and the chemosensitization function of compound Zhebei granules
10.3760/cma.j.issn.1009-9921.2018.04.008
- VernacularTitle: miRNA-17-92高表达白血病动物模型化疗敏感性及复方浙贝颗粒增敏作用研究
- Author:
Xiaolin TIAN
1
;
Yayue ZHANG
2
;
Zhen YANG
2
;
Yong ZHAO
3
;
Yamei XU
2
Author Information
1. Department of Hematology, Shandong Provincial Hospital of Traditional Chinese Medicine, Jinan 250011, China
2. Department of Hematology and Oncology, Dongzhimen Hospital Affiliated to Beijing University of Traditional Chinese Medicine, Beijing 100700, China
3. National Laboratory of Biomembrane and Membrane Bioengineering, Institute of Zoology Chinese Academy of Sciences, Beijing 100101, China
- Publication Type:Journal Article
- Keywords:
Leukemia;
Models, animal;
Compound Zhebei granules;
Chemotherapy sensitization
- From:
Journal of Leukemia & Lymphoma
2018;27(4):222-227
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the effect of miR-17-92 overexpression on the chemosensitivity of leukemia mice and the chemosensitivity of compound Zhebei granules.
Methods:The miR-17-92 over-expressed cells and L1210 cells were conventionally infused into each DBA/2N mouse through the vena caudalis at the cellular concentration of 100×104. The mice were divided into 5 groups with a randomized method, including miR-17-92 high expression L1210 cell leukemia mice (miR-17-92) observation group, miRNA-17-92 chemotherapy group, miRNA-17-92 chemotherapy combined with compound Zhebei granules group, L1210 chemotherapy group and normal control group. The chemotherapy groups were given cyclophosphamide by intraperitoneal injection, or chemotherapy combined with compound Zhebei granules group plus compound Zhebei. In the course of the experiment, the routine blood and white blood cell classification were checked every 7 days. The animals were killed on the 15th day or before dying. Peripheral blood routine and white blood cell classification were detected, the proportion of leukemia cells was checked by using bone marrow morphology. Furthermore, it was necessary to weigh the spleen and observe histopathological changes. P-glycoprotein (P-gp) expression was detected by using enzyme-linked immunosorbent assay.
Results:The difference between hemoglobin and platelet count on the 15th day after administration was statistically significant in the miRNA-17-92 observation group, miRNA-17-92 chemotherapy group, miRNA-17-92 chemotherapy combined compound Zhebei group, L1210 chemotherapy group, and normal control group (F= 5.76, P= 0.002; F= 16.90, P= 0.002); Compared with the normal control group, peripheral blood leukocyte count in the miRNA-17-92 observation group was decreased (P < 0.05). The proportion of peripheral blood leukemic cells was (37.2±13.1)%, (5.7±1.9)%, (1.3±0.8)%, (0.8±0.3)%, 0, and the proportion of myeloid leukemia cells was (26.9±11.0)%, (6.8±2.0)%, (3.2±1.0)%, (1.7±1.2)%, 0, and the difference was statistically significant (F= 24.38, P= 0.000 0; F= 19.71, P= 0.000 0). The spleen weights were (0.70±0.18), (0.20±0.07), (0.44±0.17), (0.23±0.19), (0.60±0.18) g respectively, and the difference was statistically significant (F= 8.78, P= 0.032). Chemotherapy could reduce leukemia spleen infiltration. P-gp was (33±11), (27±11), (32±11), (20±11), (17±3) ng/ml, and the difference was statistically significant (F= 10.42, P= 0.034). Compound Zhebei granules did not significantly reduce P-gp expression.
Conclusions:The overexpression of miRNA-17-92 leads to the decrease of chemotherapy response rate. Compound Zhebei granules combined with chemotherapy could improve the response rate of miR-17-92 high expression L1210 mice.
